Reata Pharmaceuticals Inc - Class A (RETA) gains 1.35% for July 21

Equities Staff  |

Reata Pharmaceuticals Inc - Class A (NASDAQ: RETA) shares gained 1.35%, or $1.75 per share, to close Wednesday at $131.44. After opening the day at $130.67, shares of Reata fluctuated between $131.82 and $127.66. 150,357 shares traded hands a decrease from their 30 day average of 447,091. Wednesday's activity brought Reata’s market cap to $4,123,051,981.

Reata is headquartered in Plano, Texas..

About Reata Pharmaceuticals Inc - Class A

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Visit Reata Pharmaceuticals Inc - Class A’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Reata Pharmaceuticals Inc - Class A and to follow the company’s latest updates, you can visit the company’s profile page here: Reata Pharmaceuticals Inc - Class A’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content